Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma

worldpharmanewsJuly 11, 2019

Tag: FDA , myeloma , isatuximab

PharmaSources Customer Service